The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy

被引:0
|
作者
Falagario, Ugo Giovanni [1 ,2 ]
Sanguedolce, Francesca [3 ]
Cormio, Angelo [4 ]
Ninivaggi, Antonella [1 ]
Finati, Marco [1 ]
Guzzi, Francesco [1 ]
Busetto, Gian Maria [1 ]
Bettocchi, Carlo [1 ]
Castellani, Daniele [4 ]
Carrieri, Giuseppe [1 ]
Cormio, Luigi [1 ,5 ]
机构
[1] Univ Foggia, Dept Urol & Renal Transplantat, Policlin Foggia, I-71122 Foggia, Italy
[2] Karolinska Inst, Dept Mol Med & Surg Solna, S-17176 Stockholm, Sweden
[3] Univ Foggia, Pathol Unit, Policlin Foggia, I-71122 Foggia, Italy
[4] Univ Politecn Marche, Dept Urol, Azienda Ospedaliero Univ Ospedali Riuniti Ancona, Via Conca 71, I-60126 Ancona, Italy
[5] Bonomo Teaching Hosp, Dept Urol, I-76123 Andria, Italy
关键词
prostate cancer; prostatic inflammation; prostate biopsy; lower urinary tract symptoms; benign prostatic obstruction; REDUCED RISK; BENIGN; HYPERPLASIA; TISSUE; MEN;
D O I
10.3390/diagnostics15020166
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is emerging evidence of an inverse association between prostatic inflammation (PI) and prostate cancer (PCa) diagnosis and outcome. The Irani score, a validated system that scores PI according to the grade of stromal infiltration (Irani G) and the aggressiveness of glandular infiltration (Irani A), has indeed been found to be inversely associated with PCa diagnosis and outcome, but the presence of two categories (G and A) makes the performance of this score suboptimal. This study aimed to determine whether a novel prostatic inflammation score (PIS) that combines Irani G and A scores better defined the risk of being diagnosed with PCa at prostate biopsy (PBx). Methods: Between January 2013 and December 2023, the Irani scores were routinely assessed on hematoxylin and eosin-stained PBx cores. The novel PIS was obtained by combining Irani G and A scores by their kernel distribution. PIS 1 included patients who scored G 0-1/A 0-1, PIS 2 those who scored G 2-3/A 0-1, and PIS 3 included those who scored G 0-3/A 2-3. Logistic regression analysis was used to test the association between the novel PIS and the risk of being diagnosed with PCa and clinically significant (cs) PCa at PBx. Results: Among the 4620 eligible patients, PCa and csPCa detection rate was 47% and 25%, respectively. Overall, 3088 (66.8%) had low Irani G and 4041 (87.5%) had low Irani A scores. Using PIS, 2971 (64%) were classified as PIS 1, 1070 (23%) as PIS 2, and 579 (13%) as PIS 3. Notably, almost one-quarter of patients had heterogeneous Irani features. Multivariable analysis pointed out a significant association between PIS and the risk of being diagnosed with PCa and csPCa; the higher the PIS, the lower the likelihood of such diagnoses. Limitations included the absence of external validation. Conclusions: The novel PIS, easily obtained during routine pathology examination, was significantly associated with the risk of being diagnosed with PCa and csPCa at PBx. While PI seems to be overall protective over PCa, the different types (stromal vs. glandular) of inflammation depicted by PIS seem to express a different risk.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Predictive value of the asymptomatic prostatic inflammation in the development of prostate cancer
    Molimard, B.
    Camparo, P.
    Desfemmes, F. -R
    Durand, X.
    Haus, R.
    Deligne, E.
    Houlgatte, A.
    Comperat, E.
    PROGRES EN UROLOGIE, 2010, 20 (07): : 508 - 514
  • [32] Inflammation and endothelial activation in Benign Prostatic Hyperplasia and Prostate Cancer
    Pace, Gianna
    Di Massimo, Caterina
    De Amicis, Daniela
    Vicentini, Carlo
    Ciancarelli, M. Giuliana Tozzi
    INTERNATIONAL BRAZ J UROL, 2011, 37 (05): : 617 - 622
  • [33] Chronic inflammation and fibrosis as risk factors of the prostatic intraepithelial neoplasia (PIN) and prostate cancer
    Gorbunova, E. N.
    Davydova, D. A.
    Krupin, V. N.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2011, (01) : 79 - 83
  • [34] Pentraxin 3: A Novel Biomarker for Predicting Progression from Prostatic Inflammation to Prostate Cancer
    Stallone, Giovanni
    Cormio, Luigi
    Netti, Giuseppe Stefano
    Infante, Barbara
    Selvaggio, Oscar
    Di Fino, Giuseppe
    Ranieri, Elena
    Bruno, Francesca
    Prattichizzo, Clelia
    Sanguedolce, Francesca
    Tortorella, Simona
    Bufo, Pantaleo
    Grandaliano, Giuseppe
    Carrieri, Giuseppe
    CANCER RESEARCH, 2014, 74 (16) : 4230 - 4238
  • [35] Prostatic inflammation is associated with benign prostatic hyperplasia rather than prostate cancer
    Falagario, U.
    Selvaggio, O.
    Carrieri, G.
    Barret, E.
    Sanguedolce, F.
    Cormio, L.
    JOURNAL OF GERONTOLOGY AND GERIATRICS, 2018, 66 (04): : 178 - 182
  • [36] Does inflammation reduce the risk of prostate cancer?
    Goldstraw, Miles A.
    Kirby, Roger S.
    BJU INTERNATIONAL, 2013, 112 (06) : 710 - 710
  • [37] PROSTATIC INFLAMMATION IN FIRST BIOPSY SPECIMENS AND URINARY PYURIA ARE PREDICTORS FOR NEGATIVE REPEAT PROSTATE BIOPSY
    Fujita, Kazutoshi
    Hosomi, Masahiro
    Nakazawa, Shigeaki
    Yamamoto, Yoshiyuki
    Hayashi, Takuji
    Tanigawa, Go
    Imamura, Ryoichi
    Fushimi, Hiroaki
    Yamaguchi, Seiji
    JOURNAL OF UROLOGY, 2011, 185 (04): : E851 - E851
  • [38] The mysterious relation between inflammation and prostate cancer
    Yu Zhao
    InfectionInternational, 2017, 6 (01) : 8 - 12
  • [39] Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer
    Kryvenko, Oleksandr N.
    Jankowski, Michelle
    Chitale, Dhananjay A.
    Tang, Deliang
    Rundle, Andrew
    Trudeau, Sheri
    Rybicki, Benjamin A.
    MODERN PATHOLOGY, 2012, 25 (07) : 1023 - 1032
  • [40] The Correlation between Inflammation, BPH and Prostate Cancer
    Djavan, Bob
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (13) : 863 - 864